Title: Effects of methylprednisolone sodium succinate in the adjuvant therapy of pediatric severe mycoplasma pneumoniae pneumonia and its influence on children’s lung function and immune status
Abstract: Objective
To investigate the effects of methylprednisolone sodium succinate in the adjuvant therapy of children with severe mycoplasma pneumoniae pneumonia (SMPP) and its influence on lung function and immune status.
Methods
A total of 224 patients with SMPP admitted to Huozhou Coal and Electricity Group General Hospital from May 2014 to May 2018 were selected and randomly divided into control group and adjuvant group, with 112 cases in each group. Children in control group were treated by conventional comprehensive treatment, and children in adjuvant group were treated by conventional comprehensive treatment plus methylprednisolone sodium succinate adjuvant therapy. The treatment effects, lung function, immune status and levels of inflammatory factors before and after treatment were compared between the two groups.
Results
After treatment, the relevant treatment times (times of lung rales disappearance, cough disappearance, lung shadow disappearance and fever abatement and hospital stay) in adiuvant group were significantly shorter than those in control group (P<0.05). The lung function indexes, such as forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FVC/FEV1 and peak expiratory flow (PEF), were significantly increased in the two groups after treatment (P<0.05); and the increases were greater in adjuvant group (P<0.05). The immune function indexes including IgA, IgG, IgM in the two groups were significantly increased after treatment (P<0.05), and the increases were greater in adjuvant group (P<0.05). The percentage of neutrophils in the two groups was significantly increased after treatment (P<0.05), while the levels of C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were significantly decreased in the two group (P<0.05), and the changes were greater in adjuvant group (P<0.05).
Conclusions
Methylprednisolone sodium succinate adjuvant therapy for SMPP can quickly relieve children’s clinical symptoms, improve lung function and immune function, and reduce inflammatory response.
Key words:
Methylprednisolone sodium succinate; Severe mycoplasma pneumoniae pneumonia; Lung function; Immune status
Publication Year: 2019
Publication Date: 2019-02-10
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot